Skip Navigation

Richard M. Stone, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chief of Staff
  • Director, Translational Research, Adult Leukemia Program
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Leukemias
  • Myelodysplastic syndromes
  • Myeloproliferative disorders

Diseases Treated

Contact Information

  • Appointments617-632-6028 (new)
    617-582-7386 x1 (follow-up)
  • Office Phone Number617-632-2168
  • Fax617-632-2933

Bio

Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.

Board Certification:

  • Hematology, 1988
  • Internal Medicine, 1984
  • Medical Oncology, 1987

Fellowship:

  • Dana-Farber Cancer Institute, Hematology/Oncology

Residency:

  • Brigham and Women's Hospital, Chief Medical Resident
  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Recent Awards:

  • Dana-Farber Cancer Institute Medical Oncology Teaching Award 2007

Research

Therapy for Acute Leukemias and Related Disorders

The primary focus of our clinical team is patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative disorders. Our practice is located in the Center for Hematologic Malignancies in the ambulatory clinic at DFCI, but we also see inpatients at Brigham and Women's Hospital. In addition to seeing patients with refractory leukemia and advanced myelodysplasia, we see others with complex or difficult cases who have been referred from outside New England and from other countries. Our goal is to provide the highest level of clinical care and improve the outcome for all patients.Our research involves identifying novel targets involved in the pathophysiology of acute leukemia and myelodysplastic syndrome. Inhibition of the FLT3 tyrosine kinase, for example, may offer benefits in AML patients - especially those whose blasts have an activating mutation in the enzyme - similar to the success of imatinib in the treatment of patients with chronic myeloid leukemia (CML). After conducting several trials with FLT3 inhibitors as single agents in myeloid malignancies, we are now focusing on combining these drugs with chemotherapeutic agents. Our laboratory continues to explore the mechanism of leukemic transformation via mutated FLT3, especially regarding activation of downstream pathways such as protein kinase A or AKT, which may be involved in key aspects of leukemogenesis such as prevention of apoptosis and promotion of self-renewal. Other areas of clinical research include targeted therapy in T cell ALL, based on inhibition of NOTCH activation, a common survival mechanism in such cells; application of intensive "pediatric-type" strategies in adults with ALL; and many novel drugs in AML in AML and MDS including histone deacetylase inhibitors, NEDD-8 inhibitors, HSP90 inhibitors, MEK inhibitors and others.

Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223.
View in: PubMed

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 Apr 01; 137(13):1792-1803.
View in: PubMed

Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nat Immunol. 2021 Apr; 22(4):520-529.
View in: PubMed

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Blood Adv. 2021 Mar 09; 5(5):1474-1482.
View in: PubMed

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 Mar 02.
View in: PubMed

Measurements of pp?ZZ production cross sections and constraints on anomalous triple gauge couplings at s=13TeV. Eur Phys J C Part Fields. 2021; 81(3):200.
View in: PubMed

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 Mar 04; 28(3):514-523.e9.
View in: PubMed

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 Feb 17.
View in: PubMed

Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 Feb 04.
View in: PubMed

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 Jan 26; 5(2):504-512.
View in: PubMed

Search for dark matter produced in association with a leptonically decaying Z boson in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2021; 81(1):13.
View in: PubMed

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021 01 06; 19(1):16-27.
View in: PubMed

Search for top squark pair production using dilepton final states in pp collision data collected at s=13TeV. Eur Phys J C Part Fields. 2021; 81(1):3.
View in: PubMed

Measurement of single-diffractive dijet production in proton-proton collisions at s=8Te with the CMS and TOTEM experiments. Eur Phys J C Part Fields. 2020; 80(12):1164.
View in: PubMed

Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. Cancer Discov. 2021 Mar; 11(3):626-637.
View in: PubMed

Evidence for Top Quark Production in Nucleus-Nucleus Collisions. Phys Rev Lett. 2020 Nov 27; 125(22):222001.
View in: PubMed

Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1166-1175.
View in: PubMed

A Deep Neural Network for Simultaneous Estimation of b Jet Energy and Resolution. Comput Softw Big Sci. 2020; 4(1):10.
View in: PubMed

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2021 Jan 01; 39(1):57-65.
View in: PubMed

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 10 13; 4(19):4945-4954.
View in: PubMed

Observation of the Production of Three Massive Gauge Bosons at sqrt[s]=13??TeV. Phys Rev Lett. 2020 Oct 09; 125(15):151802.
View in: PubMed

Observation of the B_{s}^{0}?X(3872)? Decay. Phys Rev Lett. 2020 Oct 09; 125(15):152001.
View in: PubMed

Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: A multicenter randomized clinical trial. J Vet Intern Med. 2020 Nov; 34(6):2384-2397.
View in: PubMed

Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proc Natl Acad Sci U S A. 2020 10 20; 117(42):26340-26346.
View in: PubMed

Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA. Living Rev Relativ. 2020; 23(1):3.
View in: PubMed

Indigenous Alaskans demand a voice in research on warming. Science. 2020 09 11; 369(6509):1284-1285.
View in: PubMed

Studies of Charm Quark Diffusion inside Jets Using Pb-Pb and pp Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2020 Sep 04; 125(10):102001.
View in: PubMed

Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep; 34(9):2543.
View in: PubMed

Search for physics beyond the standard model in events with jets and two same-sign or at least three charged leptons in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2020; 80(8):752.
View in: PubMed

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 08 11; 4(15):3528-3549.
View in: PubMed

Study of central exclusive production in proton-proton collisions at s=5.02 and 13TeV. Eur Phys J C Part Fields. 2020; 80(8):718.
View in: PubMed

Measurements of tt[over ¯]H Production and the CP Structure of the Yukawa Interaction between the Higgs Boson and Top Quark in the Diphoton Decay Channel. Phys Rev Lett. 2020 Aug 07; 125(6):061801.
View in: PubMed

Siberia's 'gateway to the underworld' hit by heat wave. Science. 2020 08 07; 369(6504):612-613.
View in: PubMed

Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer. 2020 Nov 01; 126(21):4735-4743.
View in: PubMed

Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. Leukemia. 2021 Apr; 35(4):1188-1192.
View in: PubMed

Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma. 2020 12; 61(12):2900-2904.
View in: PubMed

New tensions dim hopes for salvaging Iran nuclear deal. Science. 2020 06 19; 368(6497):1300-1301.
View in: PubMed

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug; 7(8):e601-e612.
View in: PubMed

Mixed higher-order anisotropic flow and nonlinear response coefficients of charged particles in PbPb collisions at sNN=2.76 and 5.02 TeV. Eur Phys J C Part Fields. 2020; 80(6):534.
View in: PubMed

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged?<60 years. Leukemia. 2020 12; 34(12):3215-3227.
View in: PubMed

Measurement of the Jet Mass Distribution and Top Quark Mass in Hadronic Decays of Boosted Top Quarks in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2020 May 22; 124(20):202001.
View in: PubMed

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020 05 12; 4(9):1894-1905.
View in: PubMed

Measurement of differential cross sections and charge ratios for t-channel single top quark production in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2020; 80(5):370.
View in: PubMed

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1711-1721.
View in: PubMed

Constraints on the ?_{c1} versus ?_{c2} Polarizations in Proton-Proton Collisions at sqrt[s]=8??TeV. Phys Rev Lett. 2020 Apr 24; 124(16):162002.
View in: PubMed

Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. J Med Chem. 2020 04 23; 63(8):4256-4292.
View in: PubMed

Search for a Narrow Resonance Lighter than 200 GeV Decaying to a Pair of Muons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2020 Apr 03; 124(13):131802.
View in: PubMed

A multi-dimensional search for new heavy resonances decaying to boosted WW , WZ , or ZZ boson pairs in the dijet final state at 13  Te. Eur Phys J C Part Fields. 2020; 80(3):237.
View in: PubMed

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr; 7(4):e309-e319.
View in: PubMed

Search for direct pair production of supersymmetric partners to the t lepton in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2020; 80(3):189.
View in: PubMed

Optimal therapeutic strategies for mixed phenotype acute leukemia. Curr Opin Hematol. 2020 Mar; 27(2):95-102.
View in: PubMed

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020 02 25; 4(4):696-705.
View in: PubMed

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 02 13; 135(7):463-471.
View in: PubMed

Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leuk Lymphoma. 2020 06; 61(6):1455-1464.
View in: PubMed

Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020 04; 122(8):1175-1184.
View in: PubMed

Search for production of four top quarks in final states with same-sign or multiple leptons in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2020; 80(2):75.
View in: PubMed

Search for Supersymmetry with a Compressed Mass Spectrum in Events with a Soft t Lepton, a Highly Energetic Jet, and Large Missing Transverse Momentum in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2020 Jan 31; 124(4):041803.
View in: PubMed

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020 01 30; 135(5):371-380.
View in: PubMed

Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood Adv. 2020 01 28; 4(2):239-251.
View in: PubMed

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO Oncol Pract. 2020 06; 16(6):e464-e475.
View in: PubMed

Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020 03; 24(5):2968-2980.
View in: PubMed

Measurement of electroweak production of a W boson in association with two jets in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2020; 80(1):43.
View in: PubMed

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156.
View in: PubMed

Need for speed. Science. 2020 01 10; 367(6474):134-138.
View in: PubMed

Extraction and validation of a new set of CMS pythia8 tunes from underlying-event measurements. Eur Phys J C Part Fields. 2020; 80(1):4.
View in: PubMed

Searches for physics beyond the standard model with the MT2 variable in hadronic final states with and without disappearing tracks in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2020; 80(1):3.
View in: PubMed

U.S. military tests radiation belt cleanup in space. Science. 2020 01 03; 367(6473):9-10.
View in: PubMed

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250.
View in: PubMed

Search for Physics beyond the Standard Model in Events with Overlapping Photons and Jets. Phys Rev Lett. 2019 Dec 13; 123(24):241801.
View in: PubMed

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
View in: PubMed

Search for Low-Mass Quark-Antiquark Resonances Produced in Association with a Photon at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Dec 06; 123(23):231803.
View in: PubMed

Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. Leuk Res Rep. 2019; 12:100189.
View in: PubMed

Measurements of triple-differential cross sections for inclusive isolated-photon+jet events in pp collisions at s=8TeV. Eur Phys J C Part Fields. 2019; 79(11):969.
View in: PubMed

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. Blood. 2019 Nov 13; 134(Supplement_1):33.
View in: PubMed

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood. 2019 Nov 13; 134(Supplement_1):15.
View in: PubMed

Measurement of the average very forward energy as a function of the track multiplicity at central pseudorapidities in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(11):893.
View in: PubMed

Search for new physics in top quark production in dilepton final states in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(11):886.
View in: PubMed

Obscure Cold War nerve agents set to be banned. Science. 2019 10 25; 366(6464):404-405.
View in: PubMed

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020 01; 11(1):107-113.
View in: PubMed

Search for Subsolar Mass Ultracompact Binaries in Advanced LIGO's Second Observing Run. Phys Rev Lett. 2019 Oct 18; 123(16):161102.
View in: PubMed

Search for a Light Charged Higgs Boson Decaying to a W Boson and a CP-Odd Higgs Boson in Final States with eµµ or µµµ in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Sep 27; 123(13):131802.
View in: PubMed

Azimuthal separation in nearly back-to-back jet topologies in inclusive 2- and 3-jet events in pp collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(9):773.
View in: PubMed

Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. Leukemia. 2020 02; 34(2):358-368.
View in: PubMed

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 02; 34(2):625-629.
View in: PubMed

Measurement of exclusive ?7700  photoproduction in ultraperipheral pPb collisions at sNN=5.02Te. Eur Phys J C Part Fields. 2019; 79(8):702.
View in: PubMed

Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. Haematologica. 2020 03; 105(3):721-729.
View in: PubMed

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clin Cancer Res. 2019 11 01; 25(21):6524-6531.
View in: PubMed

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019 08 01; 381(5):432-443.
View in: PubMed

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 09 12; 134(11):867-879.
View in: PubMed

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501.
View in: PubMed

Studies of Beauty Suppression via Nonprompt D^{0} Mesons in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2019 Jul 12; 123(2):022001.
View in: PubMed

Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
View in: PubMed

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019; 10:2040620719860645.
View in: PubMed

Tests of General Relativity with GW170817. Phys Rev Lett. 2019 Jul 03; 123(1):011102.
View in: PubMed

Search for a heavy pseudoscalar boson decaying to a Z and a Higgs boson at s=13Te. Eur Phys J C Part Fields. 2019; 79(7):564.
View in: PubMed

North Korea's HIV epidemic emerges from the shadows. Science. 2019 06 28; 364(6447):1215-1216.
View in: PubMed

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687.
View in: PubMed

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019 08; 94(8):921-928.
View in: PubMed

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721.
View in: PubMed

Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019 07 25; 134(4):374-382.
View in: PubMed

Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. . 2019 08; 18(8):1451-1459.
View in: PubMed

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 06 01; 17(6):721-749.
View in: PubMed

Search for supersymmetry in events with a photon, jets, b -jets, and missing transverse momentum in proton-proton collisions at 13 Te. Eur Phys J C Part Fields. 2019; 79(5):444.
View in: PubMed

Combined measurements of Higgs boson couplings in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(5):421.
View in: PubMed

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019 11; 33(11):2599-2609.
View in: PubMed

Measurement of the tt¯ production cross section, the top quark mass, and the strong coupling constant using dilepton events in pp collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(5):368.
View in: PubMed

Search for vector-like quarks in events with two oppositely charged leptons and jets in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(4):364.
View in: PubMed

Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Res. 2019 06; 29(6):446-459.
View in: PubMed

Jet Shapes of Isolated Photon-Tagged Jets in Pb-Pb and pp Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2019 Apr 19; 122(15):152001.
View in: PubMed

Search for W Boson Decays to Three Charged Pions. Phys Rev Lett. 2019 Apr 19; 122(15):151802.
View in: PubMed

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica. 2020 01; 105(1):161-169.
View in: PubMed

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385.
View in: PubMed

Measurement of the top quark mass in the all-jets final state at s=13TeV and combination with the lepton+jets channel. Eur Phys J C Part Fields. 2019; 79(4):313.
View in: PubMed

Observation of Two Excited B_{c}^{+} States and Measurement of the B_{c}^{+}(2S) Mass in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Apr 05; 122(13):132001.
View in: PubMed

Observation of Single Top Quark Production in Association with a Z Boson in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Apr 05; 122(13):132003.
View in: PubMed

Search for resonant production of second-generation sleptons with same-sign dimuon events in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(4):305.
View in: PubMed

Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies. J Am Geriatr Soc. 2019 05; 67(5):889-897.
View in: PubMed

Combination of Searches for Higgs Boson Pair Production in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Mar 29; 122(12):121803.
View in: PubMed

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
View in: PubMed

Search for dark matter produced in association with a Higgs boson decaying to a pair of bottom quarks in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(3):280.
View in: PubMed

Measurement of exclusive ? photoproduction from protons in p Pb collisions at sNN=5.02TeV. Eur Phys J C Part Fields. 2019; 79(3):277.
View in: PubMed

Measurement of associated production of a W boson and a charm quark in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(3):269.
View in: PubMed

Search for Narrow H? Resonances in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Mar 01; 122(8):081804.
View in: PubMed

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019 03 07; 176(6):1265-1281.e24.
View in: PubMed

Reduced disease severity following therapeutic treatment with angiotensin 1-7 in a mouse model of multiple sclerosis. Neurobiol Dis. 2019 07; 127:87-100.
View in: PubMed

Constraining the p-Mode-g-Mode Tidal Instability with GW170817. Phys Rev Lett. 2019 Feb 15; 122(6):061104.
View in: PubMed

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia. 2019 07; 33(7):1620-1634.
View in: PubMed

Study of the underlying event in top quark pair production in pp collisions at 13 Te. Eur Phys J C Part Fields. 2019; 79(2):123.
View in: PubMed

Search for single production of vector-like quarks decaying to a top quark and a W boson in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(2):90.
View in: PubMed

Search for rare decays of Z and Higgs bosons to J/? and a photon in proton-proton collisions at s = 13 TeV. Eur Phys J C Part Fields. 2019; 79(2):94.
View in: PubMed

Search for the Higgs Boson Decaying to Two Muons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Jan 18; 122(2):021801.
View in: PubMed

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559.
View in: PubMed

Search for Dark Matter Particles Produced in Association with a Top Quark Pair at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Jan 11; 122(1):011803.
View in: PubMed

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 07; 33(7):1747-1758.
View in: PubMed

Measurement of differential cross sections for inclusive isolated-photon and photon+jet production in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(1):20.
View in: PubMed

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.
View in: PubMed

Observation of Medium-Induced Modifications of Jet Fragmentation in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV Using Isolated Photon-Tagged Jets. Phys Rev Lett. 2018 Dec 14; 121(24):242301.
View in: PubMed

Search for Leptoquarks Coupled to Third-Generation Quarks in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Dec 14; 121(24):241802.
View in: PubMed

Search for Subsolar-Mass Ultracompact Binaries in Advanced LIGO's First Observing Run. Phys Rev Lett. 2018 Dec 07; 121(23):231103.
View in: PubMed

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 02 14; 133(7):676-687.
View in: PubMed

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528.
View in: PubMed

Evidence for the Associated Production of a Single Top Quark and a Photon in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Nov 30; 121(22):221802.
View in: PubMed

Measurement of differential cross sections for Z boson production in association with jets in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2018; 78(11):965.
View in: PubMed

Studies of Bs2*(5840)0 and Bs1(5830)0 mesons including the observation of the Bs2*(5840)0?B0KS0 decay in proton-proton collisions at s=8TeV. Eur Phys J C Part Fields. 2018; 78(11):939.
View in: PubMed

Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549.
View in: PubMed

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112.
View in: PubMed

Measurement of the top quark mass with lepton+jets final states using pp collisions at s=13TeV. Eur Phys J C Part Fields. 2018; 78(11):891.
View in: PubMed

Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. Haematologica. 2018 11; 103(11):1758-1759.
View in: PubMed

The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence. Gynecol Oncol. 2018 11; 151(2):187-189.
View in: PubMed

GW170817: Measurements of Neutron Star Radii and Equation of State. Phys Rev Lett. 2018 Oct 19; 121(16):161101.
View in: PubMed

Search for Pair-Produced Resonances Each Decaying into at Least Four Quarks in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Oct 05; 121(14):141802.
View in: PubMed

Observation of the Z??l^{+}l^{-} Decay in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Oct 05; 121(14):141801.
View in: PubMed

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer. 2018 12 15; 124(24):4601-4609.
View in: PubMed

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia. 2019 03; 33(3):771-775.
View in: PubMed

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018 12; 32(12):2546-2557.
View in: PubMed

Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. J Neuropathol Exp Neurol. 2018 10 01; 77(10):877-882.
View in: PubMed

Search for new physics in dijet angular distributions using proton-proton collisions at s=13TeV and constraints on dark matter and other models. Eur Phys J C Part Fields. 2018; 78(9):789.
View in: PubMed

Observation of Higgs Boson Decay to Bottom Quarks. Phys Rev Lett. 2018 Sep 21; 121(12):121801.
View in: PubMed

What FLT3 inhibitor holds the greatest promise? Best Pract Res Clin Haematol. 2018 12; 31(4):401-404.
View in: PubMed

Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML. Cancer Cell. 2018 09 10; 34(3):355-357.
View in: PubMed

Renewed sanctions strangle science in Iran. Science. 2018 Sep 07; 361(6406):961.
View in: PubMed

Measurement of the Z/?*?tt cross section in pp collisions at s=13TeV and validation of t lepton analysis techniques. Eur Phys J C Part Fields. 2018; 78(9):708.
View in: PubMed

Search for third-generation scalar leptoquarks decaying to a top quark and a t lepton at s=13Te. Eur Phys J C Part Fields. 2018; 78(9):707.
View in: PubMed

Measurement of the weak mixing angle using the forward-backward asymmetry of Drell-Yan events in pp collisions at 8 TeV. Eur Phys J C Part Fields. 2018; 78(9):701.
View in: PubMed

Measurement of charged particle spectra in minimum-bias events from proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2018; 78(9):697.
View in: PubMed

Observation of the ?_{b1}(3P) and ?_{b2}(3P) and Measurement of their Masses. Phys Rev Lett. 2018 Aug 31; 121(9):092002.
View in: PubMed

Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018 09; 93(9):1119-1126.
View in: PubMed

Elliptic Flow of Charm and Strange Hadrons in High-Multiplicity p+Pb Collisions at sqrt[s_{NN}]=8.16??TeV. Phys Rev Lett. 2018 Aug 24; 121(8):082301.
View in: PubMed

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
View in: PubMed

Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract. 2019 Sep; 25(6):1349-1356.
View in: PubMed

Constraining Gluon Distributions in Nuclei Using Dijets in Proton-Proton and Proton-Lead Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2018 Aug 10; 121(6):062002.
View in: PubMed

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv. 2018 07 24; 2(14):1705-1718.
View in: PubMed

Application of multi-state models in cancer clinical trials. Clin Trials. 2018 10; 15(5):489-498.
View in: PubMed

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692.
View in: PubMed

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018 07 10; 2(13):1645-1650.
View in: PubMed

Measurement of prompt and nonprompt charmonium suppression in PbPb collisions at 5.02 TeV. Eur Phys J C Part Fields. 2018; 78(6):509.
View in: PubMed

Search for Physics Beyond the Standard Model in Events with High-Momentum Higgs Bosons and Missing Transverse Momentum in Proton-Proton Collisions at 13 TeV. Phys Rev Lett. 2018 Jun 15; 120(24):241801.
View in: PubMed

Observation of tt[over ¯]H Production. Phys Rev Lett. 2018 Jun 08; 120(23):231801.
View in: PubMed

Measurement of b hadron lifetimes in pp collisions at s=8TeV. Eur Phys J C Part Fields. 2018; 78(6):457.
View in: PubMed

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia. 2018 12; 32(12):2536-2545.
View in: PubMed

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21; 378(25):2386-2398.
View in: PubMed

Search for Heavy Neutral Leptons in Events with Three Charged Leptons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Jun 01; 120(22):221801.
View in: PubMed

Search for the X(5568) State Decaying into B_{s}^{0}p^{±} in Proton-Proton Collisions at sqrt[s]=8??TeV. Phys Rev Lett. 2018 May 18; 120(20):202005.
View in: PubMed

Search for Narrow Resonances in the b-Tagged Dijet Mass Spectrum in Proton-Proton Collisions at sqrt[s]=8??TeV. Phys Rev Lett. 2018 May 18; 120(20):201801.
View in: PubMed

Search for Tensor, Vector, and Scalar Polarizations in the Stochastic Gravitational-Wave Background. Phys Rev Lett. 2018 May 18; 120(20):201102.
View in: PubMed

Measurement of Prompt D^{0} Meson Azimuthal Anisotropy in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2018 May 18; 120(20):202301.
View in: PubMed

Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One. 2018; 13(5):e0197049.
View in: PubMed

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
View in: PubMed

Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol. 2018 05 01; 4(5):686-693.
View in: PubMed

Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA. Living Rev Relativ. 2018; 21(1):3.
View in: PubMed

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leuk Lymphoma. 2018 11; 59(11):2723-2726.
View in: PubMed

Search for new physics in events with a leptonically decaying Z boson and a large transverse momentum imbalance in proton-proton collisions at s = 13 TeV. Eur Phys J C Part Fields. 2018; 78(4):291.
View in: PubMed

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436).
View in: PubMed

Measurement of associated Z + charm production in proton-proton collisions at s=8TeV. Eur Phys J C Part Fields. 2018; 78(4):287.
View in: PubMed

Suppression of Excited ? States Relative to the Ground State in Pb-Pb Collisions at sqrt[s]_{NN}=5.02??TeV. Phys Rev Lett. 2018 Apr 06; 120(14):142301.
View in: PubMed

Measurement of the Splitting Function in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2018 Apr 06; 120(14):142302.
View in: PubMed

Study of dijet events with a large rapidity gap between the two leading jets in pp collisions at s=7TeV. Eur Phys J C Part Fields. 2018; 78(3):242.
View in: PubMed

Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 03 07; 10(431).
View in: PubMed

GW170817: Implications for the Stochastic Gravitational-Wave Background from Compact Binary Coalescences. Phys Rev Lett. 2018 Mar 02; 120(9):091101.
View in: PubMed

Observation of Correlated Azimuthal Anisotropy Fourier Harmonics in pp and p+Pb Collisions at the LHC. Phys Rev Lett. 2018 Mar 02; 120(9):092301.
View in: PubMed

Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018 02 27; 2(4):444-453.
View in: PubMed

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018 06; 32(6):1338-1348.
View in: PubMed

Measurements of the pp?ZZ production cross section and the Z?4l branching fraction, and constraints on anomalous triple gauge couplings at s=13TeV. Eur Phys J C Part Fields. 2018; 78(2):165.
View in: PubMed

Observation of Electroweak Production of Same-Sign W Boson Pairs in the Two Jet and Two Same-Sign Lepton Final State in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Feb 23; 120(8):081801.
View in: PubMed

Search for standard model production of four top quarks with same-sign and multilepton final states in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2018; 78(2):140.
View in: PubMed

Inclusive Search for a Highly Boosted Higgs Boson Decaying to a Bottom Quark-Antiquark Pair. Phys Rev Lett. 2018 Feb 16; 120(7):071802.
View in: PubMed

First Search for Nontensorial Gravitational Waves from Known Pulsars. Phys Rev Lett. 2018 Jan 19; 120(3):031104.
View in: PubMed

A concise review of BCL-2 inhibition in acute myeloid leukemia. Expert Rev Hematol. 2018 02; 11(2):145-154.
View in: PubMed

Observation of Top Quark Production in Proton-Nucleus Collisions. Phys Rev Lett. 2017 Dec 15; 119(24):242001.
View in: PubMed

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 2017 Dec 14; 17(1):852.
View in: PubMed

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget. 2018 Jan 12; 9(4):4354-4365.
View in: PubMed

Search for dark matter produced in association with heavy-flavor quark pairs in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2017; 77(12):845.
View in: PubMed

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):E49-E52.
View in: PubMed

Search for Evidence of the Type-III Seesaw Mechanism in Multilepton Final States in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2017 Dec 01; 119(22):221802.
View in: PubMed

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
View in: PubMed

Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 Nov 09; 377(19):1903.
View in: PubMed

Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 11 09; 377(19):1903.
View in: PubMed

Measurements of the associated production of a Z boson and b jets in pp collisions at s=8TeV. Eur Phys J C Part Fields. 2017; 77(11):751.
View in: PubMed

Measurement of the triple-differential dijet cross section in proton-proton collisions at s=8TeV and constraints on parton distribution functions. Eur Phys J C Part Fields. 2017; 77(11):746.
View in: PubMed

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Dec 15; 8(66):109973-109984.
View in: PubMed

Search for new phenomena with the MT2 variable in the all-hadronic final state produced in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2017; 77(10):710.
View in: PubMed

GW170817: Observation of Gravitational Waves from a Binary Neutron Star Inspiral. Phys Rev Lett. 2017 Oct 20; 119(16):161101.
View in: PubMed

Measurement of the B^{±} Meson Nuclear Modification Factor in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2017 Oct 13; 119(15):152301.
View in: PubMed

Search for Supersymmetry in pp Collisions at sqrt[s]=13??TeV in the Single-Lepton Final State Using the Sum of Masses of Large-Radius Jets. Phys Rev Lett. 2017 Oct 13; 119(15):151802.
View in: PubMed

GW170814: A Three-Detector Observation of Gravitational Waves from a Binary Black Hole Coalescence. Phys Rev Lett. 2017 Oct 06; 119(14):141101.
View in: PubMed

Search for Charged Higgs Bosons Produced via Vector Boson Fusion and Decaying into a Pair of W and Z Bosons Using pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2017 Oct 06; 119(14):141802.
View in: PubMed

Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
View in: PubMed

Which new agents will be incorporated into frontline therapy in acute myeloid leukemia? Best Pract Res Clin Haematol. 2017 12; 30(4):312-316.
View in: PubMed

Search for heavy resonances that decay into a vector boson and a Higgs boson in hadronic final states at s=13TeV. Eur Phys J C Part Fields. 2017; 77(9):636.
View in: PubMed

Search for Low Mass Vector Resonances Decaying to Quark-Antiquark Pairs in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2017 Sep 15; 119(11):111802.
View in: PubMed

Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Adv. 2017 Sep 26; 1(21):1786-1789.
View in: PubMed

Search for physics beyond the standard model in events with two leptons of same sign, missing transverse momentum, and jets in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2017; 77(9):578.
View in: PubMed

Study of Jet Quenching with Z+jet Correlations in Pb-Pb and pp Collisions at sqrt[s]_{NN}=5.02??TeV. Phys Rev Lett. 2017 Aug 25; 119(8):082301.
View in: PubMed

Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice? J Oncol Pract. 2017 08; 13(8):471-480.
View in: PubMed

Measurement of the jet mass in highly boosted [Formula: see text] events from pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2017; 77(7):467.
View in: PubMed

Measurement of double-differential cross sections for top quark pair production in pp collisions at [Formula: see text][Formula: see text] and impact on parton distribution functions. Eur Phys J C Part Fields. 2017; 77(7):459.
View in: PubMed

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 08; 8(32):52026-52044.
View in: PubMed

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06.
View in: PubMed

Acute Promyelocytic Leukemia: A Perspective. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):543-544.
View in: PubMed

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 07; 15(7):926-957.
View in: PubMed

Calcium Pyrophosphate Crystal Inflammatory Arthritis (Pseudogout) with Myelodysplastic Syndrome: A New Paraneoplastic Syndrome? J Rheumatol. 2017 07; 44(7):1101-1102.
View in: PubMed

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017 Sep 15; 8(40):67639-67650.
View in: PubMed

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 08 03; 377(5):454-464.
View in: PubMed

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 08 10; 130(6):722-731.
View in: PubMed

GW170104: Observation of a 50-Solar-Mass Binary Black Hole Coalescence at Redshift 0.2. Phys Rev Lett. 2017 Jun 02; 118(22):221101.
View in: PubMed

Measurement of the top quark mass using single top quark events in proton-proton collisions at [Formula: see text] TeV. Eur Phys J C Part Fields. 2017; 77(5):354.
View in: PubMed

Searches for pair production of third-generation squarks in [Formula: see text][Formula: see text] pp collisions. Eur Phys J C Part Fields. 2017; 77(5):327.
View in: PubMed

The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. Hematol Oncol Clin North Am. 2017 08; 31(4):663-680.
View in: PubMed

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20; 35(24):2745-2753.
View in: PubMed

A search for new phenomena in pp collisions at [Formula: see text] in final states with missing transverse momentum and at least one jet using the [Formula: see text] variable. Eur Phys J C Part Fields. 2017; 77(5):294.
View in: PubMed

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica. 2017 08; 102(8):1391-1400.
View in: PubMed

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017 06 15; 129(24):3175-3183.
View in: PubMed

Measurement of prompt and nonprompt [Formula: see text] production in [Formula: see text] and [Formula: see text] collisions at [Formula: see text]. Eur Phys J C Part Fields. 2017; 77(4):269.
View in: PubMed

Relative Modification of Prompt ?(2S) and J/? Yields from pp to PbPb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2017 Apr 21; 118(16):162301.
View in: PubMed

Suppression and azimuthal anisotropy of prompt and nonprompt [Formula: see text] production in PbPb collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2017; 77(4):252.
View in: PubMed

Measurement of the WZ production cross section in pp collisions at [Formula: see text] and 8[Formula: see text] and search for anomalous triple gauge couplings at [Formula: see text]. Eur Phys J C Part Fields. 2017; 77(4):236.
View in: PubMed

Directional Limits on Persistent Gravitational Waves from Advanced LIGO's First Observing Run. Phys Rev Lett. 2017 Mar 24; 118(12):121102.
View in: PubMed

Observation of Charge-Dependent Azimuthal Correlations in p-Pb Collisions and Its Implication for the Search for the Chiral Magnetic Effect. Phys Rev Lett. 2017 Mar 24; 118(12):122301.
View in: PubMed

Upper Limits on the Stochastic Gravitational-Wave Background from Advanced LIGO's First Observing Run. Phys Rev Lett. 2017 Mar 24; 118(12):121101.
View in: PubMed

No evidence for microsatellite instability in acute myeloid leukemia. Leukemia. 2017 06; 31(6):1474-1476.
View in: PubMed

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017 10; 31(10):2211-2218.
View in: PubMed

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017 06 15; 129(24):3165-3174.
View in: PubMed

Measurement of the [Formula: see text] production cross section using events in the [Formula: see text] final state in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2017; 77(3):172.
View in: PubMed

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer J. 2017 03 10; 7(3):e542.
View in: PubMed

Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 05; 177(4):562-566.
View in: PubMed

3 + 7 + FLT3 inhibitors: 1 + 1 ? 2. Blood. 2017 03 02; 129(9):1061-1062.
View in: PubMed

Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. Curr Opin Hematol. 2017 03; 24(2):139-145.
View in: PubMed

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313.
View in: PubMed

Measurement of the production cross section of a W boson in association with two b jets in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2017; 77(2):92.
View in: PubMed

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017 Jan 24; 1(5):331-340.
View in: PubMed

Search for Dark Matter and Supersymmetry with a Compressed Mass Spectrum in the Vector Boson Fusion Topology in Proton-Proton Collisions at sqrt[s]=8??TeV. Phys Rev Lett. 2017 Jan 13; 118(2):021802.
View in: PubMed

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017 Mar 30; 129(13):1763-1767.
View in: PubMed

Measurements of the [Formula: see text] production cross section in lepton+jets final states in pp collisions at 8 [Formula: see text] and ratio of 8 to 7 [Formula: see text] cross sections. Eur Phys J C Part Fields. 2017; 77(1):15.
View in: PubMed

Novel Therapeutics in Acute Myeloid Leukemia. Am Soc Clin Oncol Educ Book. 2017; 37:495-503.
View in: PubMed

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):60-87.
View in: PubMed

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90.
View in: PubMed

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164.
View in: PubMed

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
View in: PubMed

Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion. 2017 02; 57(2):289-295.
View in: PubMed

An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395.
View in: PubMed

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2017 06; 31(6):1278-1285.
View in: PubMed

Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours. Nat Cell Biol. 2016 Dec; 18(12):1346-1356.
View in: PubMed

Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res. 2017 01 01; 77(1):207-218.
View in: PubMed

Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol. 2017 Jan; 176(1):86-91.
View in: PubMed

Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Leuk Lymphoma. 2017 06; 58(6):1412-1423.
View in: PubMed

Thrombosis in AML? Yes, but when to worry? Blood. 2016 10 06; 128(14):1784-1785.
View in: PubMed

Measurement of dijet azimuthal decorrelation in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(10):536.
View in: PubMed

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39.
View in: PubMed

Measurement of the differential cross section and charge asymmetry for inclusive [Formula: see text] production at [Formula: see text] TeV. Eur Phys J C Part Fields. 2016; 76(8):469.
View in: PubMed

Search for direct pair production of supersymmetric top quarks decaying to all-hadronic final states in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(8):460.
View in: PubMed

Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. 2016 Aug 16; 7(33):53515-53525.
View in: PubMed

Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016 10 06; 128(14):1845-1853.
View in: PubMed

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 10; 6(10):1106-1117.
View in: PubMed

Measurement of the double-differential inclusive jet cross section in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(8):451.
View in: PubMed

Search for new physics in same-sign dilepton events in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(8):439.
View in: PubMed

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol. 2016 Oct; 175(2):226-236.
View in: PubMed

Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica. 2016 12; 101(12):1516-1523.
View in: PubMed

Search for Resonant Production of High-Mass Photon Pairs in Proton-Proton Collisions at sqrt[s]=8 and 13 TeV. Phys Rev Lett. 2016 Jul 29; 117(5):051802.
View in: PubMed

Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2. Leukemia. 2016 11; 30(11):2254-2258.
View in: PubMed

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
View in: PubMed

Measurement of the [Formula: see text] cross section in pp collisions at [Formula: see text] TeVand limits on anomalous gauge couplings. Eur Phys J C Part Fields. 2016; 76(7):401.
View in: PubMed

Search for Narrow Resonances in Dijet Final States at sqrt[s]=8??TeV with the Novel CMS Technique of Data Scouting. Phys Rev Lett. 2016 Jul 15; 117(3):031802.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

Measurement of [Formula: see text] production with additional jet activity, including [Formula: see text] quark jets, in the dilepton decay channel using pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(7):379.
View in: PubMed

Search for heavy resonances decaying to two Higgs bosons in final states containing four b quarks. Eur Phys J C Part Fields. 2016; 76(7):371.
View in: PubMed

Measurement of inclusive jet production and nuclear modifications in pPb collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(7):372.
View in: PubMed

MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987.
View in: PubMed

Autoimmunity and Inflammation in Myelodysplastic Syndromes. Acta Haematol. 2016; 136(2):108-17.
View in: PubMed

Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016 06 27; 213(7):1285-306.
View in: PubMed

GW151226: Observation of Gravitational Waves from a 22-Solar-Mass Binary Black Hole Coalescence. Phys Rev Lett. 2016 Jun 17; 116(24):241103.
View in: PubMed

Forward-backward asymmetry of Drell-Yan lepton pairs in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2016; 76(6):325.
View in: PubMed

Properties of the Binary Black Hole Merger GW150914. Phys Rev Lett. 2016 Jun 17; 116(24):241102.
View in: PubMed

Search for lepton flavour violating decays of heavy resonances and quantum black holes to an [Formula: see text] pair in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(6):317.
View in: PubMed

GW150914: First results from the search for binary black hole coalescence with Advanced LIGO. Phys Rev D. 2016 Jun 15; 93(12).
View in: PubMed

Characterization of transient noise in Advanced LIGO relevant to gravitational wave signal GW150914. Class Quantum Gravity. 2016 Jul 07; 33(13).
View in: PubMed

Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9.
View in: PubMed

Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. 2016 May 31; 7(22):32641-51.
View in: PubMed

Tests of General Relativity with GW150914. Phys Rev Lett. 2016 Jun 03; 116(22):221101.
View in: PubMed

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia. 2016 10; 30(10):2112-2116.
View in: PubMed

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017 01; 31(1):143-150.
View in: PubMed

Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
View in: PubMed

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17; 7(20):29131-42.
View in: PubMed

Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88.
View in: PubMed

Search for massive WH resonances decaying into the [Formula: see text] final state at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2016; 76(5):237.
View in: PubMed

Measurement of Long-Range Near-Side Two-Particle Angular Correlations in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2016 Apr 29; 116(17):172302.
View in: PubMed

Transplantation after Remission in Mixed Phenotype Acute Leukemia: A Good Idea. Biol Blood Marrow Transplant. 2016 06; 22(6):971-972.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

GW150914: Implications for the Stochastic Gravitational-Wave Background from Binary Black Holes. Phys Rev Lett. 2016 Apr 01; 116(13):131102.
View in: PubMed

GW150914: The Advanced LIGO Detectors in the Era of First Discoveries. Phys Rev Lett. 2016 Apr 01; 116(13):131103.
View in: PubMed

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):341-349.e1.
View in: PubMed

The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1977-9.
View in: PubMed

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016 Aug; 51(8):1121-6.
View in: PubMed

Event generator tunes obtained from underlying event and multiparton scattering measurements. Eur Phys J C Part Fields. 2016; 76:155.
View in: PubMed

Measurement of the [Formula: see text] production cross section in the all-jets final state in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2016; 76:128.
View in: PubMed

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett. 2016 May 12; 7(5):476-81.
View in: PubMed

Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. Br J Haematol. 2016 06; 173(5):713-21.
View in: PubMed

Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306.
View in: PubMed

Search for Narrow Resonances Decaying to Dijets in Proton-Proton Collisions at v[s]=13??TeV. Phys Rev Lett. 2016 Feb 19; 116(7):071801.
View in: PubMed

Observation of Gravitational Waves from a Binary Black Hole Merger. Phys Rev Lett. 2016 Feb 12; 116(6):061102.
View in: PubMed

Prospects for Observing and Localizing Gravitational-Wave Transients with Advanced LIGO and Advanced Virgo. Living Rev Relativ. 2016; 19(1):1.
View in: PubMed

Measurement of the Top Quark Pair Production Cross Section in Proton-Proton Collisions at v[s]=13??TeV. Phys Rev Lett. 2016 Feb 05; 116(5):052002.
View in: PubMed

Study of B Meson Production in p+Pb Collisions at v[S(NN)]=5.02 TeV Using Exclusive Hadronic Decays. Phys Rev Lett. 2016 Jan 22; 116(3):032301.
View in: PubMed

Measurement of differential cross sections for Higgs boson production in the diphoton decay channel in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76:13.
View in: PubMed

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia. 2016 07; 30(7):1586-9.
View in: PubMed

Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016 Feb; 91(2):199-204.
View in: PubMed

Measurement of the differential cross section for top quark pair production in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2015; 75(11):542.
View in: PubMed

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75.
View in: PubMed

Measurements of the [Formula: see text][Formula: see text] production cross sections in the [Formula: see text] channel in proton-proton collisions at [Formula: see text] and [Formula: see text] and combined constraints on triple gauge couplings. Eur Phys J C Part Fields. 2015; 75(10):511.
View in: PubMed

Should older adults with AML receive post-remission therapy? Best Pract Res Clin Haematol. 2015 Jun-Sep; 28(2-3):106-11.
View in: PubMed

Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206.
View in: PubMed

Impact of sleep disturbance in myelodysplastic syndromes (MDS). J Clin Oncol. 2015 Oct 10; 33(29_suppl):99.
View in: PubMed

Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015; 4:30.
View in: PubMed

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10; 13:294.
View in: PubMed

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leuk Res. 2015 Sep 09.
View in: PubMed

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015 Oct 29; 373(18):1733-47.
View in: PubMed

Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Oct 01; 21(19):4262-9.
View in: PubMed

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016 Jan; 30(1):190-9.
View in: PubMed

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. . 2015 Oct; 14(10):2249-59.
View in: PubMed

Constraints on the pMSSM, AMSB model and on other models from the search for long-lived charged particles in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2015; 75(7):325.
View in: PubMed

New Models of Therapy: When Acute Leukemia Becomes Chronic. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1856-7.
View in: PubMed

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan; 30(1):173-81.
View in: PubMed

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
View in: PubMed

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia. 2016 Mar; 30(3):754-7.
View in: PubMed

CLINICAL PROBLEM-SOLVING. A Man with Fever, Cough, and Rash. N Engl J Med. 2015 Jul 02; 373(1):74-80.
View in: PubMed

Distributions of topological observables in inclusive three- and four-jet events in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(7):302.
View in: PubMed

Evidence for Collective Multiparticle Correlations in p-Pb Collisions. Phys Rev Lett. 2015 Jul 03; 115(1):012301.
View in: PubMed

Constraints on parton distribution functions and extraction of the strong coupling constant from the inclusive jet cross section in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(6):288.
View in: PubMed

Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia. 2016 Feb; 30(2):501-4.
View in: PubMed

Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015 Jul; 6(4):288-98.
View in: PubMed

Search for a standard model Higgs boson produced in association with a top-quark pair and decaying to bottom quarks using a matrix element method. Eur Phys J C Part Fields. 2015; 75(6):251.
View in: PubMed

Nuclear effects on the transverse momentum spectra of charged particles in pPb collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(5):237.
View in: PubMed

Search for dark matter, extra dimensions, and unparticles in monojet events in proton-proton collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(5):235.
View in: PubMed

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16; 126(3):291-9.
View in: PubMed

Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Mod Pathol. 2015 Jul; 28(7):965-76.
View in: PubMed

Precise determination of the mass of the Higgs boson and tests of compatibility of its couplings with the standard model predictions using proton collisions at 7 and 8[Formula: see text]. Eur Phys J C Part Fields. 2015; 75(5):212.
View in: PubMed

Combined Measurement of the Higgs Boson Mass in pp Collisions at sqrt[s]=7 and 8 TeV with the ATLAS and CMS Experiments. Phys Rev Lett. 2015 May 15; 114(19):191803.
View in: PubMed

Measurement of J/? and ?(2S) Prompt Double-Differential Cross Sections in pp Collisions at sqrt[s]=7 TeV. Phys Rev Lett. 2015 May 15; 114(19):191802.
View in: PubMed

Measurement of the inclusive 3-jet production differential cross section in proton-proton collisions at 7 TeV and determination of the strong coupling constant in the TeV range. Eur Phys J C Part Fields. 2015; 75(5):186.
View in: PubMed

Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
View in: PubMed

Search for decays of stopped long-lived particles produced in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2015; 75(4):151.
View in: PubMed

Measurements of differential and double-differential Drell-Yan cross sections in proton-proton collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(4):147.
View in: PubMed

Search for monotop signatures in proton-proton collisions at vs=8??TeV. Phys Rev Lett. 2015 Mar 13; 114(10):101801.
View in: PubMed

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
View in: PubMed

Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):261-72.
View in: PubMed

Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1? Curr Opin Hematol. 2015 Mar; 22(2):123-31.
View in: PubMed

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015 Jul; 29(7):1555-1563.
View in: PubMed

Search for displaced supersymmetry in events with an electron and a muon with large impact parameters. Phys Rev Lett. 2015 Feb 13; 114(6):061801.
View in: PubMed

Measurement of electroweak production of two jets in association with a Z boson in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2015; 75(2):66.
View in: PubMed

Study of vector boson scattering and search for new physics in events with two same-sign leptons and two jets. Phys Rev Lett. 2015 Feb 06; 114(5):051801.
View in: PubMed

How I treat mixed-phenotype acute leukemia. Blood. 2015 Apr 16; 125(16):2477-85.
View in: PubMed

Measurement of prompt ?(2S) to J/? yield ratios in Pb-Pb and p-p collisions at sqrt[sNN]=2.76??TeV. Phys Rev Lett. 2014 Dec 31; 113(26):262301.
View in: PubMed

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
View in: PubMed

Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):18679-84.
View in: PubMed

Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2015 Feb; 39(2):204-10.
View in: PubMed

Improved upper limits on the stochastic gravitational-wave background from 2009-2010 LIGO and Virgo data. Phys Rev Lett. 2014 Dec 05; 113(23):231101.
View in: PubMed

Search for heavy neutrinos and [Formula: see text] bosons with right-handed couplings in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2014; 74(11):3149.
View in: PubMed

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
View in: PubMed

Measurement of differential cross sections for the production of a pair of isolated photons in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2014; 74(11):3129.
View in: PubMed

Observation of the diphoton decay of the Higgs boson and measurement of its properties. Eur Phys J C Part Fields. 2014; 74(10):3076.
View in: PubMed

Searches for electroweak production of charginos, neutralinos, and sleptons decaying to leptons and W, Z, and Higgs bosons in pp collisions at 8 TeV. Eur Phys J C Part Fields. 2014; 74(9):3036.
View in: PubMed

Evidence of b-jet quenching in PbPb collisions at v(s(NN))=2.76??TeV. Phys Rev Lett. 2014 Sep 26; 113(13):132301.
View in: PubMed

Measurement of top quark-antiquark pair production in association with a W or Z boson in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2014; 74(9):3060.
View in: PubMed

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23; 124(17):2705-12.
View in: PubMed

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015 Mar; 29(3):567-75.
View in: PubMed

Interactive medical case. A man with fever, cough, and rash. N Engl J Med. 2014 Aug 21; 371(8):e11.
View in: PubMed

Measurement of jet multiplicity distributions in [Formula: see text] production in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2014; 74(8):3014.
View in: PubMed

Search for invisible decays of Higgs bosons in the vector boson fusion and associated ZH production modes. Eur Phys J C Part Fields. 2014; 74(8):2980.
View in: PubMed

AML genomics for the clinician. Semin Hematol. 2014 Oct; 51(4):322-9.
View in: PubMed

Measurement of WZ and ZZ production in pp collisions at [Formula: see text] in final states with b-tagged jets. Eur Phys J C Part Fields. 2014; 74(8):2973.
View in: PubMed

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34.
View in: PubMed

De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
View in: PubMed

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87.
View in: PubMed

Search for gravitational waves associated with ?-ray bursts detected by the interplanetary network. Phys Rev Lett. 2014 Jul 04; 113(1):011102.
View in: PubMed

High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer. Cancer Res. 2014 Sep 15; 74(18):4983-95.
View in: PubMed

Probing color coherence effects in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2014; 74(6):2901.
View in: PubMed

Observation of the associated production of a single top quark and a W boson in pp collisions at sqrt[s] = 8 TeV. Phys Rev Lett. 2014 Jun 13; 112(23):231802.
View in: PubMed

Study of the production of charged pions, kaons, and protons in pPb collisions at [Formula: see text]5.02[Formula: see text]. Eur Phys J C Part Fields. 2014; 74(6):2847.
View in: PubMed

Measurement of inclusive W and Z boson production cross sections in pp collisions at sqrt[s] = 8 TeV. Phys Rev Lett. 2014 May 16; 112(19):191802.
View in: PubMed

Measurements of tt spin correlations and top-quark polarization using dilepton final states in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2014 May 09; 112(18):182001.
View in: PubMed

Search for flavor-changing neutral currents in top-quark decays t ? Zq in pp collisions at sqrt[s] = 8 TeV. Phys Rev Lett. 2014 May 02; 112(17):171802.
View in: PubMed

Search for top-quark partners with charge 5/3 in the same-sign dilepton final state. Phys Rev Lett. 2014 May 02; 112(17):171801.
View in: PubMed

Search for top squark and Higgsino production using diphoton Higgs boson decays. Phys Rev Lett. 2014 Apr 25; 112(16):161802.
View in: PubMed

Measurement of the top-quark mass in all-jets [Formula: see text] events in pp collisions at [Formula: see text] TeV. Eur Phys J C Part Fields. 2014; 74(4):2758.
View in: PubMed

Constraints on cosmic strings from the LIGO-Virgo gravitational-wave detectors. Phys Rev Lett. 2014 Apr 04; 112(13):131101.
View in: PubMed

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia. 2014 Aug; 28(8):1754-1758.
View in: PubMed

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014 Jun 01; 120(11):1670-6.
View in: PubMed

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014 May 01; 123(18):2816-25.
View in: PubMed

SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10; 25(2):226-42.
View in: PubMed

Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. . 2014 May; 13(5):1194-205.
View in: PubMed

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014 Feb 20; 32(6):548-56.
View in: PubMed

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 06; 123(6):905-13.
View in: PubMed

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75.
View in: PubMed

Jet and underlying event properties as a function of charged-particle multiplicity in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(12):2674.
View in: PubMed

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014 Jun; 28(6):1252-1258.
View in: PubMed

A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014 Mar 01; 20(5):1135-45.
View in: PubMed

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014 Jan 30; 123(5):734-42.
View in: PubMed

Search for top squarks in R-parity-violating supersymmetry using three or more leptons and b-tagged jets. Phys Rev Lett. 2013 Nov 27; 111(22):221801.
View in: PubMed

Searches for new physics using the tt¯ invariant mass distribution in pp collisions at vs=8 TeV. Phys Rev Lett. 2013 Nov 22; 111(21):211804.
View in: PubMed

A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4.
View in: PubMed

Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. . 2013 Dec; 12(12):2651-62.
View in: PubMed

Search for supersymmetry in hadronic final states with missing transverse energy using the variables aT and b-quark multiplicity in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(9):2568.
View in: PubMed

Measurement of the Bs(0)?µ+ µ- branching fraction and search for B(0)?µ+ µ- with the CMS experiment. Phys Rev Lett. 2013 Sep 06; 111(10):101804.
View in: PubMed

Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Curr Cancer Drug Targets. 2013 Sep; 13(7):735-48.
View in: PubMed

Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1047-55.
View in: PubMed

Inclusive search for supersymmetry using razor variables in pp collisions at vs=7 TeV. Phys Rev Lett. 2013 Aug 23; 111(8):081802.
View in: PubMed

MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79.
View in: PubMed

Measurement of masses in the [Formula: see text] system by kinematic endpoints in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(7):2494.
View in: PubMed

Search for physics beyond the standard model in events with t leptons, jets, and large transverse momentum imbalance in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(7):2493.
View in: PubMed

Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013 Jul; 11(7):838-74.
View in: PubMed

Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20.
View in: PubMed

Search for a standard-model-like Higgs boson with a mass in the range 145 to 1000 GeV at the LHC. Eur Phys J C Part Fields. 2013; 73(6):2469.
View in: PubMed

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013 Oct; 27(10):2023-31.
View in: PubMed

Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. J Oncol Pract. 2013 Sep; 9(5):e228-33.
View in: PubMed

Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013 Sep; 37(9):998-1003.
View in: PubMed

Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013 May 24; 3:e117.
View in: PubMed

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20.
View in: PubMed

Search for supersymmetry in pp collisions at [Formula: see text] TeV in events with a single lepton, jets, and missing transverse momentum. Eur Phys J C Part Fields. 2013; 73(5):2404.
View in: PubMed

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013 Jun 10; 31(17):2086-93.
View in: PubMed

Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2013 Jul; 37(7):747-51.
View in: PubMed

Consolidation chemotherapy for adults with AML in first remission: is there a best choice? J Clin Oncol. 2013 Jun 10; 31(17):2067-9.
View in: PubMed

Measurement of associated production of vector bosons and top quark-antiquark pairs in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2013 Apr 26; 110(17):172002.
View in: PubMed

Search for pair-produced dijet resonances in four-jet final states in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2013 Apr 05; 110(14):141802.
View in: PubMed

Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology. Expert Rev Hematol. 2013 Apr; 6(2):127-9.
View in: PubMed

SYK regulates mTOR signaling in AML. Leukemia. 2013 Nov; 27(11):2118-28.
View in: PubMed

Acute myeloid leukemia in first remission: to choose transplantation or not? J Clin Oncol. 2013 Apr 01; 31(10):1262-6.
View in: PubMed

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One. 2013; 8(2):e56473.
View in: PubMed

Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett. 2013 Feb 22; 110(8):081803.
View in: PubMed

Search for pair production of third-generation leptoquarks and top squarks in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2013 Feb 22; 110(8):081801.
View in: PubMed

Measurement of the ?1S, ?2S, and ?3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2013 Feb 22; 110(8):081802.
View in: PubMed

Measurement of the sum of WW and WZ production with W+dijet events in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(2):2283.
View in: PubMed

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013 Apr; 161(1):117-27.
View in: PubMed

Measurement of the azimuthal anisotropy of neutral pions in Pb-Pb collisions at sqrt[s](NN)] = 2.76 TeV. Phys Rev Lett. 2013 Jan 25; 110(4):042301.
View in: PubMed

Evidence for associated production of a single top quark and W boson in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2013 Jan 11; 110(2):022003.
View in: PubMed

Search for heavy neutrinos and W(R) bosons with right-handed couplings in a left-right symmetric model in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2012 Dec 28; 109(26):261802.
View in: PubMed

Study of the Dijet mass spectrum in pp ? W+jets events at sqrt[s] = 7 TeV. Phys Rev Lett. 2012 Dec 21; 109(25):251801.
View in: PubMed

Measurement of the relative prompt production rate of ?c2 and ?c1 in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2012; 72(12):2251.
View in: PubMed

Observation of sequential ? suppression in PbPb collisions. Phys Rev Lett. 2012 Nov 30; 109(22):222301.
View in: PubMed

Is it time to revisit standard post-remission therapy? Best Pract Res Clin Haematol. 2012 Dec; 25(4):437-41.
View in: PubMed

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9.
View in: PubMed

Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at vs = 7 TeV. Phys Rev Lett. 2012 Oct 26; 109(17):171803.
View in: PubMed

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012 Nov 29; 120(23):4649-52.
View in: PubMed

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012 Oct 12; 151(2):344-55.
View in: PubMed

Measurement of the pseudorapidity and centrality dependence of the transverse energy density in Pb-Pb collisions at v(s(NN))=2.76 TeV. Phys Rev Lett. 2012 Oct 12; 109(15):152303.
View in: PubMed

Search for a W' or techni-? decaying into WZ in pp Collisions at sqrt[s] = 7??TeV. Phys Rev Lett. 2012 Oct 05; 109(14):141801.
View in: PubMed

Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
View in: PubMed

Search for a light pseudoscalar Higgs boson in the dimuon decay channel in pp collisions at vs = 7 TeV. Phys Rev Lett. 2012 Sep 21; 109(12):121801.
View in: PubMed

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012 Dec 20; 30(36):4515-23.
View in: PubMed

Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2012 Sep 14; 109(11):111806.
View in: PubMed

Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012 Oct 15; 18(20):5761-72.
View in: PubMed

Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett. 2012 Aug 17; 109(7):071803.
View in: PubMed

NCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Netw. 2012 Aug; 10(8):984-1021.
View in: PubMed

Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76??TeV. Phys Rev Lett. 2012 Jul 13; 109(2):022301.
View in: PubMed

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11.
View in: PubMed

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
View in: PubMed

Search for dark matter and large extra dimensions in pp collisions yielding a photon and missing transverse energy. Phys Rev Lett. 2012 Jun 29; 108(26):261803.
View in: PubMed

Observation of a new ?b baryon. Phys Rev Lett. 2012 Jun 22; 108(25):252002.
View in: PubMed

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8.
View in: PubMed

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct; 26(10):2233-44.
View in: PubMed

Search for the standard model Higgs boson in the decay channel H?ZZ?4l in pp collisions at vs=7 TeV. Phys Rev Lett. 2012 Mar 16; 108(11):111804.
View in: PubMed

Search for signatures of extra dimensions in the diphoton mass spectrum at the large hadron collider. Phys Rev Lett. 2012 Mar 16; 108(11):111801.
View in: PubMed

The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar; 122(3):935-47.
View in: PubMed

Directional limits on persistent gravitational waves using LIGO S5 science data. Phys Rev Lett. 2011 Dec 30; 107(27):271102.
View in: PubMed

Search for a vectorlike quark with charge 2/3 in t+Z events from pp collisions at vs=7 TeV. Phys Rev Lett. 2011 Dec 30; 107(27):271802.
View in: PubMed

AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD. Leuk Res. 2012 Feb; 36(2):205-11.
View in: PubMed

Treatment of elderly acute myeloid leukemia patients. Curr Treat Options Oncol. 2011 Dec; 12(4):341-53.
View in: PubMed

Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett. 2011 Nov 25; 107(22):221804.
View in: PubMed

Search for new physics with a monojet and missing transverse energy in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 Nov 11; 107(20):201804.
View in: PubMed

Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML? Best Pract Res Clin Haematol. 2011 Dec; 24(4):509-14.
View in: PubMed

Search for B(s)(0) ? µ+ µ- and B(0) ? µ+ µ- decays in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2011 Nov 04; 107(19):191802.
View in: PubMed

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in: PubMed

Measurement of the inclusive jet cross section in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 Sep 23; 107(13):132001.
View in: PubMed

Search for three-jet resonances in pp collisions at square root(s)=7??TeV. Phys Rev Lett. 2011 Sep 02; 107(10):101801.
View in: PubMed

Measurement of the t-channel single top quark production cross section in pp collisions at vs=7??TeV. Phys Rev Lett. 2011 Aug 26; 107(9):091802.
View in: PubMed

Image defocus and altered retinal gene expression in chick: clues to the pathogenesis of ametropia. Invest Ophthalmol Vis Sci. 2011 Jul 29; 52(8):5765-77.
View in: PubMed

Indications of suppression of excited ? states in Pb-Pb collisions at v(s(NN))=2.76 TeV. Phys Rev Lett. 2011 Jul 29; 107(5):052302.
View in: PubMed

Lenalidomide in AML: del(5q) or who? Blood. 2011 Jul 21; 118(3):481-2.
View in: PubMed

Measurement of the polarization of W bosons with large transverse momenta in W + jets events at the LHC. Phys Rev Lett. 2011 Jul 08; 107(2):021802.
View in: PubMed

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol. 2011 Jul; 86(7):625-7.
View in: PubMed

Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011 Dec; 35(12):1611-5.
View in: PubMed

Measurement of the B0 production cross section in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2011 Jun 24; 106(25):252001.
View in: PubMed

Search for neutral minimal supersymmetric standard model Higgs bosons decaying to tau pairs in pp collisions at vs=7 TeV. Phys Rev Lett. 2011 Jun 10; 106(23):231801.
View in: PubMed

Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood. 2011 Jul 28; 118(4):903-15.
View in: PubMed

Search for supersymmetry in pp collisions at v7 TeV in events with two photons and missing transverse energy. Phys Rev Lett. 2011 May 27; 106(21):211802.
View in: PubMed

Study of Z Boson Production in PbPb Collisions at vS(NN)=2.76 TeV. Phys Rev Lett. 2011 May 27; 106(21):212301.
View in: PubMed

A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). J Clin Oncol. 2011 May 20; 29(15_suppl):6520.
View in: PubMed

Vaginal bleeding in women with leukemia. J Clin Oncol. 2011 May 20; 29(15_suppl):6577.
View in: PubMed

CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS199.
View in: PubMed

Measurement of dijet angular distributions and search for quark compositeness in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 May 20; 106(20):201804.
View in: PubMed

Search for pair production of second-generation scalar leptoquarks in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 May 20; 106(20):201803.
View in: PubMed

Search for pair production of first-generation scalar leptoquarks in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 May 20; 106(20):201802.
View in: PubMed

Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011; 16(6):904-11.
View in: PubMed

Dijet azimuthal decorrelations in pp collisions at vs=7 TeV. Phys Rev Lett. 2011 Mar 25; 106(12):122003.
View in: PubMed

MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70.
View in: PubMed

Measurement of the B(+) production cross section in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2011 Mar 18; 106(11):112001.
View in: PubMed

Acute myeloid leukemia. J Natl Compr Canc Netw. 2011 Mar; 9(3):280-317.
View in: PubMed

Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011 Apr 01; 29(10):1290-6.
View in: PubMed

Measurement of the isolated prompt photon production cross section in pp collisions at vs=7??TeV. Phys Rev Lett. 2011 Feb 25; 106(8):082001.
View in: PubMed

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011 May; 25(5):800-7.
View in: PubMed

Genomic alterations in myeloid neoplasms with novel, apparently balanced translocations. Cancer Genet. 2011 Feb; 204(2):68-76.
View in: PubMed

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301.
View in: PubMed

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 01; 29(7):789-96.
View in: PubMed

Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett. 2011 Jan 07; 106(1):011801.
View in: PubMed

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011 Jan; 9(1):30-56.
View in: PubMed

Search for quark compositeness with the dijet centrality ratio in pp collisions at vs=7 TeV. Phys Rev Lett. 2010 Dec 31; 105(26):262001.
View in: PubMed

Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010 Dec; 85(12):956-7.
View in: PubMed

Search for dijet resonances in 7 TeV pp collisions at CMS. Phys Rev Lett. 2010 Nov 19; 105(21):211801.
View in: PubMed

New agents in post-remission therapy. Best Pract Res Clin Haematol. 2010 Dec; 23(4):475-9.
View in: PubMed

Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010 Dec; 24(12):2100-9.
View in: PubMed

Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. . 2010 Sep 01; 10(5):483-91.
View in: PubMed

Discovery and characterization of novel mutant FLT3 kinase inhibitors. . 2010 Sep; 9(9):2468-77.
View in: PubMed

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 01; 28(28):4339-45.
View in: PubMed

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7.
View in: PubMed

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33.
View in: PubMed

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Nov 04; 116(18):3622-6.
View in: PubMed

First measurement of Bose-Einstein correlations in proton-proton collisions at vs=0.9 and 2.36 TeV at the LHC. Phys Rev Lett. 2010 Jul 16; 105(3):032001.
View in: PubMed

Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett. 2010 Jul 09; 105(2):022002.
View in: PubMed

Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol Cancer Res. 2010 Jul; 8(7):986-93.
View in: PubMed

CNS relapse in acute promyeloctyic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):e409-11.
View in: PubMed

Utility of digital stereo images for optic disc evaluation. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5667-74.
View in: PubMed

The role of molecular tests in acute myelogenous leukemia treatment decisions. Curr Hematol Malig Rep. 2010 Apr; 5(2):109-17.
View in: PubMed

Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr; 24(2):389-406.
View in: PubMed

Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients. Leuk Res. 2010 Jul; 34(7):939-41.
View in: PubMed

Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66.
View in: PubMed

NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2009 Dec 29; 7 Suppl 9:S1-16.
View in: PubMed

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in: PubMed

Prognostic factors in AML in relation to (ab)normal karyotype. Best Pract Res Clin Haematol. 2009 Dec; 22(4):523-8.
View in: PubMed

Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94.
View in: PubMed

Screens, iron, and leukemia. Blood. 2009 Oct 01; 114(14):2857-8.
View in: PubMed

Langerhans cell histiocytosis following acute leukemia in an adult. Am J Hematol. 2009 Oct; 84(10):693-4.
View in: PubMed

Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression. Mol Cell Biol. 2009 Nov; 29(21):5911-22.
View in: PubMed

An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature. 2009 Aug 20; 460(7258):990-4.
View in: PubMed

Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol. 2009 Aug; 7(8):1-14; quiz 2 p following 14.
View in: PubMed

Iron chelation therapy in myelodysplastic syndrome - Cui bono? Leukemia. 2009 Aug; 23(8):1373.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009 Aug 27; 114(9):1736-45.
View in: PubMed

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61.
View in: PubMed

Management of related donor care: a European survey. Bone Marrow Transplant. 2010 Jan; 45(1):97-101.
View in: PubMed

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20; 27(21):3472-9.
View in: PubMed

A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol. 2009 May 20; 27(15_suppl):7048.
View in: PubMed

Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS). J Clin Oncol. 2009 May 20; 27(15_suppl):7007.
View in: PubMed

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun; 12(3):81-9.
View in: PubMed

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7.
View in: PubMed

How I treat patients with myelodysplastic syndromes. Blood. 2009 Jun 18; 113(25):6296-303.
View in: PubMed

Identification of AML1-ETO modulators by chemical genomics. Blood. 2009 Jun 11; 113(24):6193-205.
View in: PubMed

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9.
View in: PubMed

The role of myeloid growth factors in acute leukemia. J Natl Compr Canc Netw. 2009 Jan; 7(1):84-91.
View in: PubMed

Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93.
View in: PubMed

Are new agents really making a difference in MDS? Best Pract Res Clin Haematol. 2008 Dec; 21(4):639-46.
View in: PubMed

Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clin Adv Hematol Oncol. 2008 Dec; 6(12):1-15.
View in: PubMed

FLT3 inhibitors in acute myeloid leukemia. Expert Rev Hematol. 2008 Dec; 1(2):153-60.
View in: PubMed

Search for gravitational-wave bursts from soft gamma repeaters. Phys Rev Lett. 2008 Nov 21; 101(21):211102.
View in: PubMed

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8.
View in: PubMed

Timed sequential induction chemotherapy in AML: time for reflection. Am J Hematol. 2008 Nov; 83(11):829-30.
View in: PubMed

Acute myeloid leukemia. J Natl Compr Canc Netw. 2008 Nov; 6(10):962-93.
View in: PubMed

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7.
View in: PubMed

Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct; 6(9):902-26.
View in: PubMed

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15; 112(13):5161-70.
View in: PubMed

The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant. 2009 Jan; 43(2):141-7.
View in: PubMed

In vivo human choroidal thickness measurements: evidence for diurnal fluctuations. Invest Ophthalmol Vis Sci. 2009 Jan; 50(1):5-12.
View in: PubMed

Elevated serum ferritin in patients with a myelodysplastic syndrome: how much of a problem? Am J Hematol. 2008 Aug; 83(8):609-10.
View in: PubMed

A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64.
View in: PubMed

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Jul; 49(7):1274-8.
View in: PubMed

New agents for the treatment of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2008 Jul; 3(3):135-43.
View in: PubMed

Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 01; 26(19):3279-81.
View in: PubMed

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008 Oct 20; 26(30):4934-9.
View in: PubMed

Classification of myelodysplastic syndrome in a national registry of recently-diagnosed patients-the Patient Registries at Slone: MDS. J Clin Oncol. 2008 May 20; 26(15_suppl):6628.
View in: PubMed

Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety. J Clin Oncol. 2008 May 20; 26(15_suppl):7015.
View in: PubMed

Pharmacokinetics (PK) and pharmacodynamics (PD) of midostaurin (PKC412) in patients with acute myeloid leukemia (AML). J Clin Oncol. 2008 May 20; 26(15_suppl):7064.
View in: PubMed

Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol. 2008 May 20; 26(15_suppl):7009.
View in: PubMed

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. . 2008 May; 7(5):1121-9.
View in: PubMed

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6.
View in: PubMed

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 01; 14(5):1446-54.
View in: PubMed

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 May 01; 111(9):4788-96.
View in: PubMed

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2008 Feb; 14(2):137-80.
View in: PubMed

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008 Feb; 5(2):e35.
View in: PubMed

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood. 2008 Apr 01; 111(7):3723-34.
View in: PubMed

Lenalidomide in myelodysplastic syndromes: where do we go from here? Curr Hematol Malig Rep. 2008 Jan; 3(1):5-9.
View in: PubMed

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood. 2008 Mar 01; 111(5):2589-96.
View in: PubMed

MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007 Dec 15; 67(24):11576-84.
View in: PubMed

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007 Dec; 12(6):501-13.
View in: PubMed

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008 Feb 01; 111(3):1039-43.
View in: PubMed

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007 Oct 01; 110(7):1509-19.
View in: PubMed

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 01; 111(1):86-93.
View in: PubMed

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82.
View in: PubMed

Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2007 Apr 01; 13(7):2254-60.
View in: PubMed

Novel therapeutic agents in acute myeloid leukemia. Exp Hematol. 2007 Apr; 35(4 Suppl 1):163-6.
View in: PubMed

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
View in: PubMed

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007 Jun 15; 109(12):5151-6.
View in: PubMed

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15; 109(12):5136-42.
View in: PubMed

Torsades de pointes associated with voriconazole use. Transpl Infect Dis. 2007 Mar; 9(1):33-6.
View in: PubMed

Targeted agents in AML: much more to do. Best Pract Res Clin Haematol. 2007 Mar; 20(1):39-48.
View in: PubMed

Azacitidine: A new agent in myelodysplastic syndromes. Cancer Investigation. 2007; In Press.

Torsades DE Pointes Associated with Voriconazole Use. Tranplant Infectious Disease. 2007; 9:33-36.

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007 Jan; 13(1):78-83.
View in: PubMed

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 07; 355(23):2408-17.
View in: PubMed

Novel Therapies in Leukemia. 2006.

What's new in the treatment of lymphoma. 2006.

Acute myeloid leukemia clinical practice guidelines in oncology. 2006.

Improving treatment outcomes for patients with hematologic malignancies. Novel treatment and erythropoietic agents: A report from ASCO 2006. 2006.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15; 109(6):2303-9.
View in: PubMed

End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007 Mar 01; 109(5):1810-6.
View in: PubMed

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 05; 355(14):1456-65.
View in: PubMed

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55.
View in: PubMed

Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia. 2006 Nov; 20(11):1963-6.
View in: PubMed

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 01; 108(12):3674-81.
View in: PubMed

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15; 108(10):3477-83.
View in: PubMed

Quality of life intervention for men with biochemical recurrence of prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):18585.
View in: PubMed

Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6576.
View in: PubMed

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6585.
View in: PubMed

Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3556s-63s.
View in: PubMed

Myelodysplastic syndromes clinical practice guideliens in oncology. 2006.

Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes? J Clin Oncol. 2006 Jun 01; 24(16):2414-6.
View in: PubMed

Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006 May; 28(5):1099-103.
View in: PubMed

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15; 108(2):419-25.
View in: PubMed

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73.
View in: PubMed

Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan; 4(1):58-77.
View in: PubMed

Preliminary results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. Blood. 2006; 108:171a.

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Onc. 2006; 24:357s.

Six year followup results of a phase II study of imatinib in late chronic refractoriness/intolerance. Blood. 2006; 108:130a.

Impact of cytogenetics and prior therapy on outcome of AML and MDS after allogeneic transplantation. Blood. 2006; 108:80a.

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL)and other leukemias. J Clin Onc. 2006; 24:357s.

Preliminary results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. Blood. 2006; 108:171a.

Treatment for Acute Myeloid Leukemia in Patients Under Age 60. Clinical Malignant Hematology. 2006; 41-50.

An erythroid differentiation gene expression signature predicts response to lenalidomide in myelodysplasia. Blood. 2006; 108:754a.

FLT3 Inhibitors. Annals of Hematology. 2006; 85:Supplement 1.

Acute myeloid leukemia clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan; 4(1):16-36.
View in: PubMed

Phase IB study of PKC412, an oral FLT3 kinase inhibitor in sequential and simultaneouos combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (patients) with acute myeloid leukemia (AML) under age 61. Blood. 2006; 108:51a.

Monitoring imatinib resistance with a "polony" assay: Towards tailored therapy of chronic myelogenous leukemias (CML). Blood. 2006; 108:251a.

Phase I/II Study of Tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood. 2006; 108:51a.

Phase IB study of PKC412, an oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicni and Cytarabine (DA) Induction and High Dose cytarabine consolidation in newly diagnosed adult patients with acute myeloid leukemia (AML under age 61). Blood. 2006; 108:51a.

Acute Myeloid Leukemia in Adults Mast Cell Leukemia and Other Mast Cell Neoplasms. Cancer Medicine. 2006; 1739-1760.

Monitoring imatinib resistance with a "polony" assay: towards tailored therapy of chronic myelogenous leukemia (CML). Blood. 2006; 108:251a.

Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients less than 60 years in first complete remission (CALGB 9720). Blood. 2006; 108:129a.

Oncology: An Evidence-Based Approach. 2006.

A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood. 2006; 108:526a..

Phase III study of immunotherapy with recombinant interleukin-2(IL-2) versus no further therapy in acute myeloid leukemia (AML) patients less than or equal to 60 years in first complete remission (CALGB 9720). Blood. 2006; 108:129a.

Impact of cytogenetics and prior therapy on outcome of AML and MDS after allogeneic transplantation. Blood. 2006; 108:80a.

Six year follow-up results of a phase II study of imatinib in late chronic refractoriness/intolerance. Blood. 2006; 108:130a.

Emil is required for normal cell cycle progression in zebrafish myelopoiesis and likely functions as a haploinsufficient tumor suppresor on chromosome 6q in human leukemias. Blood. 2006; 526a.

An erythroid differentiation gene expression signature predicts response to lenalidomide in myelodysplasia. Blood. 2006; 108:754a.

Emil is required for normal cell cycle progression in zebrafish myelopoiesis and likely function as a haploinsufficient tumor suppressor on chromosome 6q in human leukemias. Blood. 2006; 108:409a.

Phase I/II study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogeneous leukemia (AML). Blood. 2006; 108:51a.

Older AML patients: fit for what?. Blood. 2006; 108:3232-3233.

Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine. J Clin Onc. 2006; 24:355s.

Targeted Therapy in AML. 2005.

Update on targeted therapy in acute myeloid leukemia. 2005.

Acute lymphoblastic leukemia: Time for T. 2005.

Progress in acute lymphoblastic leukemia and acute promyelocytic leukemia. 2005.

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006 Jan 01; 107(1):293-300.
View in: PubMed

The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res. 2005 Aug 15; 65(16):7338-47.
View in: PubMed

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4110-6.
View in: PubMed

Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML). J Clin Oncol. 2005 Jun; 23(16_suppl):2527.
View in: PubMed

Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease. Clin Adv Hematol Oncol. 2005 May; 3(5):391-7, 429.
View in: PubMed

New Treatment Options for the Elderly AML Patient. 2005.

New Advances for Managing Stomatitis in Chemotherapy and Bone Marrow Transplant Patients. 2005.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005 Jul 15; 106(2):721-4.
View in: PubMed

Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94.
View in: PubMed

MDS: practical treatment approaches for physicians and nurses. Clin Adv Hematol Oncol. 2005 Feb; 3(2):1-7.
View in: PubMed

The Lance/Karp Article Reviewed. Oncology. 2005; 19:1049-1050.

Pharmacokinetic and pharmacodynamic studies of lestaurtinib (CEP-701) and PKC412: cytotoxicity is often dependent on non-FLT3 mediated effects. Blood. 2005; 106:692a.

Leukemia derived dendritic cells (LDCs) are functionally deficient and inferior to DC/Leukemia Fusion Cells as a tumor vaccine for AML. Blood. 2005; 106:782a.

Phase IB study of PKC412, an oral FLT3 kinase inhibito in sequential and simultaneous combination with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood. 2005; 106:121a.

Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): Final results from Cancer and Leukemia Group B study 19802. Blood. 2005; 106:521a.

KIAA 1509 is a novel PDGRFB fusion primer in imatinib-responsive myeloproliferative disease associate with a t95;14)(q33;q32). Leukemia. 2005; 19:27-30.

Phase III randomized multicenter study of humanized anti-CD33 monoclonal antibody, lintuzumab, in combinatino with chemotherapy. J Clin Oncol. 2005; 23:4110-16.

Overview of the treatment of myelodysplastic syndromes. Clinical advances in hematology and oncology. 2005; 13:2-5.

Five Year followup results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory/intolerant of interferon-alpha. Blood. 2005; 106:317a.

Response rates in patients with acute myeloid leukemia (AML), treated with azacitidine, using WHO and International Working Group (IWG) criteria for myelodysplastic syndrome (MDS). Blood. 2005; 106:525a.

Myelodysplastic syndromes: biology and management. Hematology: Basic principles and practice. 2005; 1195-1208.

Metastatic cancer of unknown primary site. Harrison's Principles of Internal Medicine. 2005; 562-565.

Addition of bortezomib (Velcade) to AML induction chemotehrapy is well tolerated and results in a high complete remission rate. Blood. 2005; 106:780a.

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005 Jan; 19(1):27-30.
View in: PubMed

Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 2004 Dec; 28(12):1303-12.
View in: PubMed

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
View in: PubMed

Chronic myeloid leukemia and the application of rational drug design. Virtual Mentor. 2004 Nov 01; 6(11).
View in: PubMed

Treatment options for myelodysplastic syndromes. Cancer Control. 2004 Nov-Dec; 11(6 Suppl):7-10.
View in: PubMed

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4.
View in: PubMed

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Oct 05; 101(40):14479-84.
View in: PubMed

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005 Jan 01; 105(1):22-30.
View in: PubMed

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005 Jan 01; 105(1):54-60.
View in: PubMed

Acute Myeloid Leukemia: NCCN Practice Guidelines. 2004.

Myelodysplastic Syndromes. NCCN Practice Guidelines. 2004.

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71.
View in: PubMed

A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3024.
View in: PubMed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
View in: PubMed

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004 Apr; 18(4):809-16.
View in: PubMed

Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Semin Oncol. 2004 Apr; 31(2 Suppl 6):12-7.
View in: PubMed

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology. 2004 Mar 09; 62(5):719-25.
View in: PubMed

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42.
View in: PubMed

Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004; 98-117.
View in: PubMed

A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 199902. Blood. 2004; 104:249a.

Treatment Options for Myelodysplastic Syndromes. Cancer Control (Supplement). 2004; 11:7-10.

FLT3 Target practice. Blood. 2004; 104:915-916.

Trnasplantation Predictive of Overall and Progression Free Survival but not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS. Blood. 2004; 104:57a.

Novel Therapies in AML: Order out of Plethora. Leukemia 2004: Towards the Cure, third international meeting of the global organization against leukemia. 2004.

Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood. 2004; 104:496a.

Phase I study of PKC412 an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with daunorubicin and cytarabine (DAA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML. Blood. 2004; 104:78a.

Phase I dose escalating trial of bortezomib (Velcade) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia. Blood. 2004; 104:498a.

Safety profile of Zarnestra (tipifarnib) in patienits with relapsed and refractory acute myeloid leukemia (AML). The Hematology Journal. 2004; 5(S2):S34.

Identification of molecular predictors of response to Zarnestra (tipifarnib R115777) in relapsed and refractory acute myeloid leukemia. Blood. 2004; 104:246a.

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004; 83 Suppl 1:S89-90.
View in: PubMed

Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist. 2004; 9(3):259-70.
View in: PubMed

Acute lymphoblastic leukemia: encouraged by profiles. 2003.

Acute lymphoblastic leukemia: new genes and nascent novel combinations. 2003.

Myopia and natural lighting extremes: risk factors in Finnish army conscripts. Acta Ophthalmol Scand. 2003 Dec; 81(6):588-95.
View in: PubMed

Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003 Nov 01; 102(9):3455-6.
View in: PubMed

Leukemia in Older Patients. 2003.

Highly precise eye length measurements in children aged 3 through 12 years. Arch Ophthalmol. 2003 Jul; 121(7):985-90.
View in: PubMed

Acute and chronic leukemias: time to exploit the targets. 2003.

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82.
View in: PubMed

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003 May; 3(5):459-69.
View in: PubMed

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14.
View in: PubMed

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003 Mar 15; 97(6):1471-80.
View in: PubMed

Induction and postremission therapy: new agents. Leukemia. 2003 Mar; 17(3):496-8.
View in: PubMed

Cancer of unknown primary. Clinical Hematology and Oncology. 2003; 313-317.

Inhibition of FLT3 tyrosine kinase: an evolving therapeutic strategy in acute myeloid leukemia. 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy. 2003; 22.

Mast cell leukemia and other mast cell neoplasms. Cancer Medicine. 2003; 2157-2161.

Induction and postremission therapy: new agents. Leuk. 2003; 17:496-8.

Acute myeloid leukemia in adults. Cancer Medicine. 2003; 2095-2115.

Successful treatment of angioinvasive aspergillosis during prolonged neutropenina wiht lipsomal amphotericin, voriconazole, and caspofungin. Infect Dis in Clin Prac. 2003; 11:355-8.

Commentary on DNA methylation in MDS and AML. Highlights from the 45th Annual Meeting of the American Society of Hematology. 2003; not available.

FLT-3 tyrosine kinase (TK) inhibition: an emerging therapy in acute myeloid leukemia (AML). Chemotherapy Foundation Symposium XXI: Innovative Cancer Therapy for Tomorrow. 2003; 20-21.

Pathology and morphology of chronic leukemias and related disorders. Neoplastic Diseases of the Blood. 2003.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994-1004.

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
View in: PubMed

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov; 21(5):1041-51.
View in: PubMed

The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002 Nov-Dec; 52(6):363-71.
View in: PubMed

Older adults with acute myeloid leukemia. Curr Oncol Rep. 2002 Sep; 4(5):403-9.
View in: PubMed

New therapies in leukemia: renewed hope. J Hematother Stem Cell Res. 2002 Aug; 11(4):583-7.
View in: PubMed

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36.
View in: PubMed

Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol. 2002 Jul; 39(3 Suppl 2):4-10.
View in: PubMed

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15; 20(10):2429-40.
View in: PubMed

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530-9.
View in: PubMed

Darkness and near work: myopia and its progression in third-year law students. Ophthalmology. 2002 May; 109(5):1032-8.
View in: PubMed

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002 Mar 15; 99(6):1928-37.
View in: PubMed

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28; 346(9):645-52.
View in: PubMed

A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult Scler. 2002 Feb; 8(1):24-9.
View in: PubMed

Highlights of leukemia research: Introduction. J Clin Oncol. 2002; 7:197-201.

Leukemia in Older Adults. Practice Guidelines in Oncology (NCCN AML Guidelines). 2002.

Acute Leukemias. Intensive Care Medicine. 2002; 1295-1302.

Gemtuzumab ozogamicin given in combination with cytarabine and daunorubicini n patients less than 60 years old with untreated acute myeloid leukemia. Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow. 2002.

Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7.
View in: PubMed

The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol. 2002 Jan; 14(1):24-30.
View in: PubMed

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15; 19(18):3852-60.
View in: PubMed

Myelodysplastic syndromes standardized response criteria: further definition. Blood. 2001 Sep 15; 98(6):1985.
View in: PubMed

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001 Aug 01; 98(3):548-53.
View in: PubMed

Postremission therapy in adults with acute myeloid leukemia. Semin Hematol. 2001 Jul; 38(3 Suppl 6):17-23.
View in: PubMed

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001 Jun 01; 97(11):3574-80.
View in: PubMed

Measurement of CP-violating asymmetries in B0 decays to CP eigenstates. Phys Rev Lett. 2001 Mar 19; 86(12):2515-22.
View in: PubMed

CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9.
View in: PubMed

Elliptic flow in Au+Au collisions at square root(S)NN = 130 GeV. Phys Rev Lett. 2001 Jan 15; 86(3):402-7.
View in: PubMed

Metastatic cancer of unknown primary site. Harrison's Principles of Internal Medicine. 2001; 628-632.

Therapy of older adults with AML: CALGB studies. Acute Leukemias VIII: Prognostic factors and treatment strategies. 2001; 631-638.

Harrison's Principles of Internal Medicine. 2001.

Hematological-oncological disorders and cardiovascular disease. Heart Disease. 2001; 2223-2243.

Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec 01; 96(12):3671-4.
View in: PubMed

NCCN Practice Guidelines for Acute Myelogenous Leukemia. Oncology (Williston Park). 2000 Nov; 14(11A):53-61.
View in: PubMed

NCCN Practic Guidelines for Acute Myelogenous Leukemia. 2000.

A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5.
View in: PubMed

Acute myeloid leukemia in adults. Clinical Oncology. 2000; 2490-2510.

Acute myeloid leukemia in adults. Cancer Medicine. 2000; 1947-70.

Myelodysplastic syndromes. Molecular Hematology. 2000; 75-84.

Mast cell leukemia and other mast cell neoplasms. Cancer Medicine. 2000; 2086-89.

Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35.
View in: PubMed

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999; 340:764-71.

Astrocyte nitric oxide causes neuronal mitochondrial damage, but antioxidant release limits neuronal cell death. Ann N Y Acad Sci. 1999; 893:400-3.
View in: PubMed

Functional role for protein kinase Cbeta as a regulator of stress-activated protein kinase activation and monocytic differentiation of myeloid leukemia cells. Mol Cell Biol. 1999 Jan; 19(1):461-70.
View in: PubMed

Leukemia in the Elderly. American Society of Hematology Education Program Book. 1999; 510-6.

Interstitial pneumonitis following mitozantrone, chlorambucil and prednisolone (MCP) chemotherapy. Clin Oncol (R Coll Radiol). 1999; 11(3):184-6.
View in: PubMed

First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Alzheimer Dis Assoc Disord. 1998 Dec; 12(4):266-80.
View in: PubMed

Blood product requirements in patients undergoing elective endovascular abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg. 1998 Nov; 16(5):390-4.
View in: PubMed

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998 Sep 01; 92(5):1556-64.
View in: PubMed

Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood. 1998 Jun 15; 91(12):4496-503.
View in: PubMed

Metastic cancer of the unknown primary site. Harrison's Principles of Internal Medicine. 1998; 614-18.

Acute Leukemias. Oncology Board Review Manual. 1998; 3:1-16.

NCCN practice guidelines for the myelodysplastic syndromes. 1998; 12:53-80.

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998 Jan; 18(1):84-7.
View in: PubMed

Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11. Blood. 1997 Oct 15; 90(8):3136-41.
View in: PubMed

Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet. 1997 Oct; 17(2):171-8.
View in: PubMed

Bryostatin 1: differentiating agent from the depths. Leuk Res. 1997 May; 21(5):399-401.
View in: PubMed

Diagnosis in Oncology. Leukemia cutis. J Clin Oncol. 1997 May; 15(5):2170-1.
View in: PubMed

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47.
View in: PubMed

Mast cell leukemia and other mast cell neoplasms. Cancer Medicine. 1997; 2289-2834.

Diagnosis in Oncology. J Clin Oncol. 1997; 15:2170-71.

Harrison's Principles of Internal Medicine. 1997.

Case Records of the Massachusetts General Hospital. N Engl J Med. 1997; 337:1065-74.

Cancer Medicine Review. 1997.

Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci. 1996 Dec 13; 803:247-55.
View in: PubMed

Kessler's legacy: unfinished reform. Science. 1996 Dec 06; 274(5293):1603-4.
View in: PubMed

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol. 1996 Sep; 14(9):2486-94.
View in: PubMed

Fertility rates among lead workers and professional bus drivers: a comparative study. Ann Epidemiol. 1996 May; 6(3):201-8.
View in: PubMed

Corneal coloboma, aphakia and retinal neovascularization with anterior segment dysgenesis (Peters' anomaly). Ophthalmologica. 1996; 210(6):361-6.
View in: PubMed

Trials of 9-amino-20(S)-camptothecin. The Camptothecins: From Discovery to Patient. 1996; 803:247-255.

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995 Jun 22; 332(25):1671-7.
View in: PubMed

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995 Apr 15; 85(8):2025-37.
View in: PubMed

Uveitis associated with interleukin-3 and interleukin-6 therapy. Arch Ophthalmol. 1995 Apr; 113(4):408-9.
View in: PubMed

A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995 Apr 01; 85(7):1881-7.
View in: PubMed

Pathology and morphology of chronic leukemias and related disorders. Neoplastic Diseases of the Blood. 1995; 21-41.

Acute myeloid leukemia in adults. Clinical Oncology. 1995; 1959-76.

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994 Dec; 12(12):2535-42.
View in: PubMed

Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res. 1994 Oct; 18(10):769-76.
View in: PubMed

Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood. 1994 Jun 15; 83(12):3437-40.
View in: PubMed

Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut. 1994 Mar; 35(3):363-8.
View in: PubMed

Neuroblastoma cell-mediated leukocyte chemotaxis: lineage-specific differentiation of interleukin-8 expression. Exp Cell Res. 1994 Mar; 211(1):1-5.
View in: PubMed

All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood. 1994 Jan 15; 83(2):490-6.
View in: PubMed

Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. J Biol Chem. 1994 Jan 14; 269(2):872-8.
View in: PubMed

Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia. Advances in Bone Marrow Purging and Processing:4th International Symposium. Wiley-Liss. 1994; 47-63.

Harrison's Principles of Internal Medicine. 1994.

Metastatic cancer of the unknown primary site. Harrison's Prinicples of Internal Medicine. 1994; 1871-74.

Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia. Prog Clin Biol Res. 1994; 389:47-63.
View in: PubMed

A novel candidate autoantigen in a multiplex family with multiple sclerosis: prevalence of T-lymphocytes specific for an MBP epitope unique to myelination. J Neuroimmunol. 1993 Jul; 46(1-2):137-44.
View in: PubMed

Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by antagonists of adipogenesis. Mol Cell Biochem. 1993 Jun 9-23; 123(1-2):63-71.
View in: PubMed

Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol. 1993 Apr; 16(2):159-63.
View in: PubMed

All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cells. Leukemia. 1993 Mar; 7(3):458-62.
View in: PubMed

Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am. 1993 Feb; 7(1):47-64.
View in: PubMed

The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am. 1993 Feb; 7(1):65-79.
View in: PubMed

Mast Cell Leukemia. Cancer Medicine. 1993; 2092-96.

Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 1992 Nov 15; 80(10):2604-9.
View in: PubMed

The association between the myelodysplastic syndromes and Crohn disease. Ann Intern Med. 1992 Oct 15; 117(8):661-2.
View in: PubMed

Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol. 1992 Jun; 10(6):948-53.
View in: PubMed

Hematopoietic growth factors and leukemia. Curr Opin Oncol. 1992 Feb; 4(1):33-44.
View in: PubMed

Acute myeloid leukemia. Current therapy in Hematology/Oncology. 1992; 63-68.

Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother. 1992; 35(4):277-82.
View in: PubMed

The association between the myelodysplastic syndromes and Chron disease. Ann Int Med. 1992; 117:661-2.

Case Records of the Massachusetts General Hospital (case 17). N Engl J Med. 1992; 326:1137-46.

Effect of picibabil (OK432) on neutrophil-mediated anti-tumor activity: Implication of monocyte-derived neutophil activating factors. Cancer Immunother. 1992; 35:277-82.

Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells. FEBS Lett. 1991 Dec 02; 294(1-2):73-6.
View in: PubMed

Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. J Clin Invest. 1991 Aug; 88(2):571-7.
View in: PubMed

Harrison's Principles of Internal Medicine. 1991.

Expressino of the jun-B gene during induction of monocytic differentiation. Cell growth and differentiation. 1991; 2:43-9.

CSFs in combination with cytosine arabinoside, an inhibitor of DNA synthesis: potential strategies for the treatment of myeloid disorders. Biotechnol Ther. 1991; 2(3-4):269-83.
View in: PubMed

Expression of the jun-B gene during induction of monocytic differentiation. Cell Growth Differ. 1991 Jan; 2(1):43-9.
View in: PubMed

Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol. 1990 Dec; 144(6):1331-3; discussion 1333-4.
View in: PubMed

A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. Leukemia. 1990 Dec; 4(12):843-7.
View in: PubMed

The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990 Nov; 8(11):1913-21.
View in: PubMed

Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites. Blood. 1990 Sep 15; 76(6):1225-32.
View in: PubMed

Age-related cognitive recovery after general anesthesia. Anesth Analg. 1990 Sep; 71(3):217-24.
View in: PubMed

Relation of urinary cotinine concentrations to cigarette smoking and to exposure to other people's smoke. Thorax. 1990 May; 45(5):356-61.
View in: PubMed

Prolymphocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):457-71.
View in: PubMed

Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem. 1990 Feb 25; 265(6):3320-3.
View in: PubMed

Angiotensin II inhibits luteinizing hormone-stimulated cholesterol side chain cleavage expression and stimulates basic fibroblast growth factor expression in bovine luteal cells in primary culture. J Biol Chem. 1990 Jan 05; 265(1):5-8.
View in: PubMed

Promylocytic leukemia. Hematology/Oncology Clinics of North America. 1990; 4:457-71.

Regulation of c-jun expression by phorbol esters and tumor necrosis factor. Molecular and Cellular Biology of Cytokines. 1990; 221-6.

Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J Biol Chem. 1989 Sep 05; 264(25):14653-61.
View in: PubMed

Detection of tumor necrosis factor gene expression at a cellular level in human acute myeloid leukemias. Leukemia. 1989 Jan; 3(1):51-6.
View in: PubMed

Role of arachidonic acid metabolism in transcriptional induction of tumor necrosis factor gene expression by phorbol ester. Mol Cell Biol. 1989 Jan; 9(1):252-8.
View in: PubMed

Lovastatin and rhabdomyolysis. Ann Intern Med. 1988 Oct 15; 109(8):682-3.
View in: PubMed

Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Aug; 72(2):739-44.
View in: PubMed

Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Jul; 72(1):208-13.
View in: PubMed

MRI of periprostatic venous plexus in staging of early prostatic carcinoma. Can Assoc Radiol J. 1988 Jun; 39(2):111-4.
View in: PubMed

Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988 Mar; 71(3):690-6.
View in: PubMed

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987 Nov 15; 47(22):5846-52.
View in: PubMed

Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood. 1987 Jan; 69(1):187-91.
View in: PubMed

The treatment of myelodysplastic syndromes. Clin Haematol. 1986 Nov; 15(4):1081-107.
View in: PubMed

Further report of a prospective randomized trial comparing distal splenorenal shunt with end-to-side portacaval shunt. An analysis of encephalopathy, survival, and quality of life. Gastroenterology. 1985 Feb; 88(2):424-9.
View in: PubMed

Evaluation of Pseudomonas aeruginosa exotoxin A and elastase as virulence factors in acute lung infection. Infect Immun. 1983 Jan; 39(1):198-201.
View in: PubMed

Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol. 1982 Oct; 54(5):527-30.
View in: PubMed

The significance of fibronectin in cryoprecipitation in rheumatoid arthritis and other diseases. J Rheumatol. 1982 Jul-Aug; 9(4):514-8.
View in: PubMed

Esophagogastrectomy using the auto suture EEA surgical stapling instrument. Ann Thorac Surg. 1980 Oct; 30(4):308-12.
View in: PubMed

A prospective randomized trial of the selective distal splenorenal shunt. Surg Gynecol Obstet. 1980 Jan; 150(1):45-8.
View in: PubMed

Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis. 1979 Dec; 140(6):881-9.
View in: PubMed

Massive lower gastrointestinal bleeding: an unusual complication of Crohn's disease. Can J Surg. 1978 Sep; 21(5):444-5.
View in: PubMed

Selection of operation in patients with bleeding esophageal varices. Can Med Assoc J. 1978 Feb 18; 118(4):369-72.
View in: PubMed

Toxic megacolon: results of emergency colectomy. Can J Surg. 1977 Jan; 20(1):36-8.
View in: PubMed

Surgical treatment of hydatid disease of the liver. Can J Surg. 1976 Sep; 19(5):416-20.
View in: PubMed

Survivors of cancer in childhood. Ann Intern Med. 1976 May; 84(5):551-3.
View in: PubMed

Familial colon cancer. Cancer. 1976 Feb; 37(2):946-8.
View in: PubMed

Melanocytoma. Arch Ophthalmol. 1975 Jul; 93(7):540-1.
View in: PubMed

Benign liver cell tumors. Classification and ultrastructural pathology. Cancer. 1973 Aug; 32(2):463-70.
View in: PubMed

Bronchial arterial circulation restored after reimplantation of canine lung. Can J Surg. 1970 Jul; 13(3):243-50.
View in: PubMed

Some observations on the cause of the gastric hypersecretion following portacaval shunt. Bull Soc Int Chir. 1968 Jul-Aug; 27(4):286-90.
View in: PubMed

The nature and source of a gastric secretagogue. Observations from the obstructed portal vein. Arch Surg. 1967 Oct; 95(4):606-8.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Mayer 1B-17
Boston, MA 02215
Get Directions

Ratings

Top